Get Premium to unlock powerful stock data

Ikarian Capital, LLC Buys Biogen Inc, CRISPR Therapeutics AG, Alector Inc, Sells Eli Lilly and Co, Curis Inc, Cara Therapeutics Inc

Author's Avatar
insider
Aug 18, 2021
Article's Main Image
Investment company Ikarian Capital, LLC (Current Portfolio) buys Biogen Inc, CRISPR Therapeutics AG, Alector Inc, Cullinan Oncology Inc, ChemoCentryx Inc, sells Eli Lilly and Co, Curis Inc, Cara Therapeutics Inc, Prothena Corp PLC, I-MAB during the 3-months ended 2021Q2, according to the most recent filings of the investment company, Ikarian Capital, LLC. As of 2021Q2, Ikarian Capital, LLC owns 210 stocks with a total value of $1.2 billion. These are the details of the buys and sells.

For the details of Ikarian Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/ikarian+capital%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Ikarian Capital, LLC
  1. Biogen Inc (BIIB) - 270,000 shares, 7.61% of the total portfolio.
  2. Alnylam Pharmaceuticals Inc (ALNY) - 300,000 shares, 4.14% of the total portfolio.
  3. Intellia Therapeutics Inc (NTLA) - 294,400 shares, 3.88% of the total portfolio.
  4. Biogen Inc (BIIB) - 125,962 shares, 3.55% of the total portfolio. Shares added by 2109.86%
  5. Alnylam Pharmaceuticals Inc (ALNY) - 195,700 shares, 2.70% of the total portfolio.
New Purchase: ChemoCentryx Inc (CCXI)

Ikarian Capital, LLC initiated holding in ChemoCentryx Inc. The purchase prices were between $9.59 and $51.24, with an estimated average price of $25.26. The stock is now traded at around $13.900000. The impact to a portfolio due to this purchase was 0.51%. The holding were 471,376 shares as of 2021-06-30.

New Purchase: Anchiano Therapeutics Ltd (CMMB)

Ikarian Capital, LLC initiated holding in Anchiano Therapeutics Ltd. The purchase prices were between $75.36 and $75.36, with an estimated average price of $75.36. The stock is now traded at around $12.810000. The impact to a portfolio due to this purchase was 0.45%. The holding were 290,534 shares as of 2021-06-30.

New Purchase: Vincerx Pharma Inc (VINC)

Ikarian Capital, LLC initiated holding in Vincerx Pharma Inc. The purchase prices were between $11.33 and $19.3, with an estimated average price of $15.33. The stock is now traded at around $12.160000. The impact to a portfolio due to this purchase was 0.45%. The holding were 426,743 shares as of 2021-06-30.

New Purchase: Anchiano Therapeutics Ltd (CMMB)

Ikarian Capital, LLC initiated holding in Anchiano Therapeutics Ltd. The purchase prices were between $75.36 and $75.36, with an estimated average price of $75.36. The stock is now traded at around $12.810000. The impact to a portfolio due to this purchase was 0.45%. The holding were 290,534 shares as of 2021-06-30.

New Purchase: Iovance Biotherapeutics Inc (IOVA)

Ikarian Capital, LLC initiated holding in Iovance Biotherapeutics Inc. The purchase prices were between $16.33 and $33.07, with an estimated average price of $26.06. The stock is now traded at around $20.830000. The impact to a portfolio due to this purchase was 0.37%. The holding were 175,000 shares as of 2021-06-30.

New Purchase: Chardan Healthcare Acquisition 2 Corp (CHAQ.U)

Ikarian Capital, LLC initiated holding in Chardan Healthcare Acquisition 2 Corp. The purchase prices were between $10.27 and $11, with an estimated average price of $10.49. The stock is now traded at around $10.550000. The impact to a portfolio due to this purchase was 0.36%. The holding were 400,000 shares as of 2021-06-30.

Added: Biogen Inc (BIIB)

Ikarian Capital, LLC added to a holding in Biogen Inc by 2109.86%. The purchase prices were between $259 and $414.71, with an estimated average price of $301.69. The stock is now traded at around $346.867300. The impact to a portfolio due to this purchase was 3.39%. The holding were 125,962 shares as of 2021-06-30.

Added: CRISPR Therapeutics AG (CRSP)

Ikarian Capital, LLC added to a holding in CRISPR Therapeutics AG by 693.63%. The purchase prices were between $100.84 and $161.89, with an estimated average price of $121.54. The stock is now traded at around $119.740000. The impact to a portfolio due to this purchase was 1.38%. The holding were 119,711 shares as of 2021-06-30.

Added: Alector Inc (ALEC)

Ikarian Capital, LLC added to a holding in Alector Inc by 162.03%. The purchase prices were between $15.5 and $22.48, with an estimated average price of $18.88. The stock is now traded at around $26.900000. The impact to a portfolio due to this purchase was 0.7%. The holding were 674,723 shares as of 2021-06-30.

Added: Cullinan Oncology Inc (CGEM)

Ikarian Capital, LLC added to a holding in Cullinan Oncology Inc by 29459.60%. The purchase prices were between $24.96 and $41.67, with an estimated average price of $31.06. The stock is now traded at around $27.235000. The impact to a portfolio due to this purchase was 0.62%. The holding were 295,596 shares as of 2021-06-30.

Added: Horizon Therapeutics PLC (HZNP)

Ikarian Capital, LLC added to a holding in Horizon Therapeutics PLC by 8990.38%. The purchase prices were between $86.24 and $95.92, with an estimated average price of $92. The stock is now traded at around $104.300000. The impact to a portfolio due to this purchase was 0.42%. The holding were 54,815 shares as of 2021-06-30.

Added: ACADIA Pharmaceuticals Inc (ACAD)

Ikarian Capital, LLC added to a holding in ACADIA Pharmaceuticals Inc by 3393.11%. The purchase prices were between $19.4 and $27.42, with an estimated average price of $22.66. The stock is now traded at around $17.010000. The impact to a portfolio due to this purchase was 0.41%. The holding were 209,866 shares as of 2021-06-30.

Sold Out: Curis Inc (CRIS)

Ikarian Capital, LLC sold out a holding in Curis Inc. The sale prices were between $7.45 and $16.27, with an estimated average price of $11.35.

Sold Out: Prothena Corp PLC (PRTA)

Ikarian Capital, LLC sold out a holding in Prothena Corp PLC. The sale prices were between $21.63 and $57.65, with an estimated average price of $30.98.

Sold Out: ESSA Pharma Inc (EPIX)

Ikarian Capital, LLC sold out a holding in ESSA Pharma Inc. The sale prices were between $24.17 and $34.28, with an estimated average price of $29.12.

Sold Out: Seres Therapeutics Inc (MCRB)

Ikarian Capital, LLC sold out a holding in Seres Therapeutics Inc. The sale prices were between $18.46 and $24.36, with an estimated average price of $21.08.

Sold Out: Ardelyx Inc (ARDX)

Ikarian Capital, LLC sold out a holding in Ardelyx Inc. The sale prices were between $6.55 and $8.98, with an estimated average price of $7.37.

Sold Out: Sage Therapeutics Inc (SAGE)

Ikarian Capital, LLC sold out a holding in Sage Therapeutics Inc. The sale prices were between $54.88 and $79.29, with an estimated average price of $70.83.



Here is the complete portfolio of Ikarian Capital, LLC. Also check out:

1. Ikarian Capital, LLC's Undervalued Stocks
2. Ikarian Capital, LLC's Top Growth Companies, and
3. Ikarian Capital, LLC's High Yield stocks
4. Stocks that Ikarian Capital, LLC keeps buying
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
Rating:
NaN / 5 ( votes)

Please Login to leave a comment

Author's Avatar

insider